Mycobacterium Abscessive Pulmonary Disease
Conditions
Interventions
Experimental group:MAB-PD treatment including carrimycin
Sponsors
Shanghai Pulmonary Hospital Affiliated to Tongji University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. The subject or legal representative has signed the informed consent; 2. Aged 18 to 75 years; 3. Diagnosed as non-tuberculous mycobacterial lung disease in accordance with the "Nontuberculous Mycobacteria Diagnosis Group Standard T/CHATA001-2020"; 4. The etiology of sputum or lavage fluid culture is clearly Mycobacterium abscessus; 5. Have not received non-tuberculous mycobacteria treatment in the past; 6. Culture drug susceptibility to rule out macrolide resistance.
Exclusion criteria
Exclusion criteria: 1. Clearly combined infection with other pathogenic microorganisms, including fungi, viruses, mycoplasma, and Mycobacterium tuberculosis; 2. Participated in any clinical trial within the past 1 month; 3. Combined with primary diseases that seriously affect survival expectations: transplantation status, uremia, malignant tumor; 4. Take immune-related drugs within the past 1 month, such as spleen aminopeptide, thymosin, etc.; 5. Pregnant women, lactating women, subjects (including male subjects) who have a pregnancy plan (including sperm donation and egg donation plan) in the next 6 months or are unable to take effective contraceptive measures; 6. Patients deemed unsuitable for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Chest imaging;Early bactericidal activity;Sputum bacteria turn negative rate; | — |
Countries
China
Contacts
Public ContactSha Wei
Shanghai Pulmonary Hospital Affiliated to Tongji University
Outcome results
None listed